Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- annexinI annexin-1 annexin1 calpactinII calpactin-2 calpactin2 chromobindin9 lipocortinI phospholipase A-2 p-35 ANXA-1 ANXA-I ANXAI ANX1 ANX-1 ANXI ANX-I escherichia endogenous mediator glucocorticoid response pathway sPLA-2 LXA4 LXA-4 RvD1 RvD-1 antiinflammatory proinflammatory mAB phospholipase A2 inhibitory protein PLA2
- Product Overview:
Annexins are a superfamily of 13 proteins sharing a high degree of homology. They have in common a core C-terminal domain containing calcium and phospholipid binding motifs, allowing most of them to bind to phospholipid membranes in a calcium-dependent manner. The N-terminal domains vary between family members and provide a unique function.{30992}Annexin A1 is an endogenous mediator of inflammation, promoting resolution in a number of ways. Normally expressed in intracellular compartments, it is drawn to the cell membrane and both induced and externalized by glucocorticoid response pathways.{30993,30994} The glucocorticoid-induced production and release of annexin A1 is the primary means by which glucocorticoids function as anti-inflammatory agents. Annexin A1 inhibits the synthesis of pro-inflammatory eicosanoids by suppressing the function of sPLA2. This, in turn, limits the recruitment of neutrophils into inflammatory sites and downregulates the production of pro-inflammatory mediators by those neutrophils that enter inflammatory sites.{30995} Meanwhile, proteolytic fragments generated in response to increased expression are implicated in producing a marker for phagocytosis.{30996} Annexin A1 also functions in the resolution of inflammation by inducing neutrophil apoptosis, and promoting neutrophil clearance (efferocytosis) by macrophages. The pro-resolving functions of annexin A1 are mediated via binding to FPR2/ALX, a receptor it shares with the specific pro-resolving mediators lipoxin A4 (Item No. 90410) and resolvin D1 (Item No. 10012554).{30995} The molecule’s regulatory role has led to investigation of the downstream effects of annexin A1, including cancer, adaptive immunity, and wound repair.{30997,30998,30999} The predicted size of annexin A1 is 38.7 kDa and Cayman’s Annexin A1 Monoclonal Antibody (Clone 3F5) detects a size 39 kDa band via western blot.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.